
A pill that mimics Viagra by relaxing blood vessels and increasing blood flow to the brain can slow cognitive decline in people with Alzheimer's disease by almost a third, a global study suggests.
Alzheimer's is the most common form of dementia, a condition that is forecast to affect 153 million people worldwide by 2050. There is currently no cure.
In a stage three trial spanning 13 countries, including the UK, researchers found the tablet AR1001 slowed decline by 31% in patients with early Alzheimer's disease not receiving any other treatment.
Experts not involved with the study urged caution but said the results were "exciting" and "very promising" and could signal the arrival of a "totally new treatment" for Alzheimer's.
The findings were presented at the Clinical Trials on Alzheimer's Disease conference in Boston.
AR1001 is a phosphodiesterase-5 inhibitor and from the same family of medicines as Viagra, which is used to treat erectile dysfunction.
The South Korean company AriBio, which makes AR1001, said the drug slowed decline in 604 people taking no other drugs for Alzheimer's. In a wider group of patients taking other drugs, the tablet did not achieve statistically significant results.
Prof Tara Spires-Jones, a professor of neurodegeneration at the University of Edinburgh and a fellow at the Academy of Medical Sciences, said the results looked "very promising".
"This drug acts through boosting blood flow and likely also directly stimulating pathways in brain cells that promote learning and memory," she said.
Dr Sheona Scales, director of research at Alzheimer's Research UK, said the findings were "very encouraging", and marked "an important milestone in the search for new Alzheimer's treatments".
AR1001 was "especially interesting" because it was an oral drug that took a "different approach" to existing treatments, she said. "Rather than targeting amyloid, it acts on a specific enzyme and influences several other processes involved in brain function.
"The trial demonstrated a statistically significant slowing of clinical decline in participants who were not taking other commonly used Alzheimer's medications alongside the trial drug. However, this benefit was not significant across the overall trial group.
"Nonetheless, this is an encouraging development in Alzheimer's research and reinforces the importance of exploring different approaches to tackling this complex disease."
Dr Richard Oakley, associate director of research and innovation at Alzheimer's Society, said: "These topline results are an exciting sign that we could have a totally new treatment for early Alzheimer's disease that tackles its causes, not just its symptoms.
"AR1001 takes a novel approach, relaxing blood vessels to increase blood flow to the brain. And unlike other disease-modifying treatments that have shown benefit in late-stage trials, it is taken as a once-a-day tablet, which could make treatment simpler.
"Over the year of the trial, this drug was able to effectively slow down people's decline in memory and thinking by nearly a third, and the side-effects reported were mostly mild to moderate."
However, the drug did not seem to be as effective for people taking other drugs for Alzheimer's symptoms, so this needed further investigation, he said.
"AR1001 is from the same family of medicines as Viagra, but it is being developed specifically for Alzheimer's disease," said Oakley, adding that people should not take Viagra to try to treat Alzheimer's.
All the experts called for further trials, and said AR1001 would have to be scrutinised by the scientific community and drug regulatory bodies before it could be prescribed to treat Alzheimer's.